Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
ILMN

Illumina Inc

ILMN

116.35USD-0.78 (-0.67%)Delayed as of 08 Dec 2023, 10:00 am
Watchlist

Market Summary

USD116.35-0.78
Delayedas of 08 Dec 2023, 10:00 am
-0.67%

ILMN Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

ILMN Stock Price

View Fullscreen

ILMN RSI Chart

ILMN Valuation

Market Cap

18.5B

Price/Earnings (Trailing)

-16.46

Price/Sales (Trailing)

4.14

EV/EBITDA

-21.49

Price/Free Cashflow

109.51

ILMN Price/Sales (Trailing)

ILMN Profitability

Operating Margin

62.23%

EBT Margin

-89.82%

Return on Equity

-63.86%

Return on Assets

-35.55%

Free Cashflow Yield

0.91%

ILMN Fundamentals

ILMN Revenue

Revenue (TTM)

4.5B

Revenue Y/Y

0.36%

Revenue Q/Q

-4.85%

ILMN Earnings

Earnings (TTM)

-1.1B

Earnings Y/Y

80.24%

Earnings Q/Q

-222.22%

Price Action

52 Week Range

115.22238.55
(Low)(High)

Last 7 days

14.9%

Last 30 days

2.3%

Last 90 days

-26.0%

Trailing 12 Months

-43.8%

How does ILMN drawdown profile look like?

ILMN Financial Health

Current Ratio

1.4

ILMN Investor Care

Shares Dilution (1Y)

0.64%

Diluted EPS (TTM)

-7.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.4B4.5B4.5B0
20224.7B4.7B4.7B4.6B
20213.5B4.0B4.3B4.5B
20203.6B3.4B3.2B3.2B
20193.4B3.4B3.5B3.5B
20182.9B3.1B3.2B3.3B
20172.4B2.5B2.6B2.8B
20162.3B2.3B2.4B2.4B
20152.0B2.1B2.1B2.2B
20141.5B1.6B1.7B1.9B
20131.2B1.3B1.3B1.4B
20121.0B1.0B1.1B1.1B
2011993.1M1.1B1.1B1.1B
2010692.7M743.1M822.0M902.7M
2009596.5M619.8M643.0M666.3M
2008000573.2M

Latest Insider Trading transactions for ILMN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 07, 2023
hoyt aimee l
sold
-35,544
112
-315
svp, chief people officer
Nov 05, 2023
ericksen scott d
sold (taxes)
-34,529
112
-306
vp, chief accounting officer
Nov 05, 2023
rollins carissa
sold (taxes)
-45,587
112
-404
svp, chief information officer
Nov 05, 2023
goswami joydeep
sold (taxes)
-212,929
112
-1,887
svp, chief financial officer
Nov 05, 2023
barnard steven
sold (taxes)
-62,400
112
-553
svp, chief technology officer
Nov 05, 2023
reeves kathryne gambrell
sold (taxes)
-81,921
112
-726
svp, chief marketing officer
Nov 05, 2023
tousi susan h
sold (taxes)
-200,968
112
-1,781
svp, chief commercial officer
Nov 05, 2023
hoyt aimee l
sold (taxes)
-136,424
112
-1,209
svp, chief people officer
Nov 05, 2023
pegels kevin carl
sold (taxes)
-86,322
112
-765
chief of global operations
Nov 05, 2023
dadswell charles
sold (taxes)
-171,855
112
-1,523
svp, general counsel

1–10 of 50

Which funds bought or sold ILMN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
added
42.65
2,180,250
51,220,400
0.04%
Dec 06, 2023
VisionPoint Advisory Group, LLC
added
344
23,681
34,181
0.01%
Dec 04, 2023
Phoenix Holdings Ltd.
added
119
167,792
458,622
-%
Dec 04, 2023
TUCKER ASSET MANAGEMENT LLC
unchanged
-
-552
1,510
-%
Dec 01, 2023
B. Riley Wealth Advisors, Inc.
reduced
-70.04
-1,263,830
356,516
0.01%
Nov 30, 2023
Neo Ivy Capital Management
sold off
-100
-1,831,000
-
-%
Nov 29, 2023
Decheng Capital Management III (Cayman), LLC
unchanged
-
-4,059,930
11,100,300
3.55%
Nov 28, 2023
IMA Wealth, Inc.
reduced
-0.96
-177,554
468,537
0.12%
Nov 27, 2023
TRUST CO OF VERMONT
sold off
-100
-9,937
-
-%
Nov 27, 2023
BANQUE PICTET & CIE SA
unchanged
-
-513,448
1,403,820
0.02%

1–10 of 39

Latest Funds Activity

Are funds buying ILMN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ILMN
No. of Funds

Schedule 13G FIlings of Illumina Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Dec 05, 2023
baillie gifford & co
3.36%
5,332,416
SC 13G/A
Nov 20, 2023
baillie gifford & co
5.44%
8,608,269
SC 13G/A
Oct 10, 2023
vanguard group inc
11.35%
17,966,765
SC 13G/A
Feb 14, 2023
edgewood management llc
4.1%
6,478,370
SC 13G/A
Feb 09, 2023
vanguard group inc
8.28%
13,022,627
SC 13G/A
Jan 31, 2023
blackrock inc.
7.7%
12,051,653
SC 13G/A
Jan 20, 2023
baillie gifford & co
10.64%
16,743,103
SC 13G/A
Feb 14, 2022
edgewood management llc
5.6%
8,742,202
SC 13G
Feb 03, 2022
blackrock inc.
7.5%
11,784,218
SC 13G/A
Jan 20, 2022
baillie gifford & co
13.10%
20,480,537
SC 13G/A

Recent SEC filings of Illumina Inc

View All Filings
Date Filed Form Type Document
Dec 05, 2023
SC 13G/A
Major Ownership Report
Nov 20, 2023
SC 13G/A
Major Ownership Report
Nov 13, 2023
10-Q
Quarterly Report
Nov 13, 2023
8-K/A
Current Report
Nov 09, 2023
4
Insider Trading
Nov 09, 2023
8-K
Current Report
Nov 09, 2023
8-K/A
Current Report
Nov 07, 2023
4
Insider Trading
Nov 07, 2023
144
Notice of Insider Sale Intent
Nov 07, 2023
4
Insider Trading

ILMN Fair Value

Loading...

Peers (Alternatives to Illumina Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
161.6B
29.6B
10.34% -18.45%
27.32
5.47
-5.39% -12.54%
43.5B
3.6B
23.81% 24.51%
52.81
12.11
7.43% 22.86%
37.7B
7.0B
16.41% -16.29%
33.28
5.39
5.03% -14.68%
15.1B
9.3B
1.76% -9.25%
19.85
1.63
-9.69% -38.22%
11.7B
2.4B
-0.52% 41.53%
-41.63
4.88
19.99% 60.62%
MID-CAP
10.4B
4.2B
10.89% -4.83%
21.89
2.47
11.49% 8.84%
8.6B
1.8B
2.53% 36.18%
31.61
4.85
29.62% 20.49%
6.9B
988.7M
32.77% 50.65%
-13.81
6.97
27.41% 8.51%
4.0B
919.1M
16.80% 19.47%
-149.36
4.32
73.02% -172.93%
3.1B
535.8M
0.15% -45.50%
-7.16
5.78
24.38% 26.34%
SMALL-CAP
526.9M
297.1M
46.76% -25.50%
-5.82
1.77
-6.74% -21.60%
70.8M
21.4M
-81.37% -93.35%
-0.62
3.3
-8.80% -39.66%
31.8M
9.2M
-16.29% -21.48%
-1.8
3.46
16.43% 48.38%
13.9M
16.1M
12.50% -25.52%
-1.98
0.86
-8.51% 41.77%
120.4K
-
-82.76% -93.43%
0
0.76
-57.78% -93.13%

Illumina Inc News

Latest updates
Stockhouse Publishing07 Dec 202304:03 pm23 hours ago
MarketBeat07 Dec 202302:27 pm24 hours ago
InvestorsObserver06 Dec 202308:03 pm43 hours ago
Nasdaq06 Dec 202307:00 pm44 hours ago
London South East06 Dec 202302:29 pm2 days ago
MarketBeat06 Dec 202301:35 pm2 days ago
DirectorsTalk Interviews05 Dec 202302:12 pm3 days ago
London South East04 Dec 202311:56 pm3 days ago
Simply Wall St03 Dec 202302:53 pm5 days ago
InvestorsObserver01 Dec 202307:27 pm6 days ago
GlobeNewswire28 Nov 202312:45 am10 days ago
GlobeNewswire26 Nov 202302:00 am12 days ago
InvestorsObserver20 Nov 202307:51 pm17 days ago
Business Wire20 Nov 202308:00 am18 days ago
MarketWatch17 Nov 202310:12 pm20 days ago

Financials for Illumina Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-4.8%1,1191,1761,0871,0841,1151,1621,2231,1991,1081,1261,093953794633859953907838846867853
Cost Of Revenue-2.0%435444432411398395408382338324329323268205240290259265262278256
Gross Profit-6.6%684732655673717767815818770802764630526428619662648573584590597
Operating Expenses75.4%1,4388207198004,3741,3466317761,315615571497364332430394340368380393356
  S&GA Expenses-32.7%303450378433146410308426879413374298192177274233189202211217197
  R&D Expenses-12.0%315358341346325327323350436202197199172155156161151166169176159
EBITDA Margin100.0%--0.83*-0.97*-0.89*-0.82*0.05*0.25*0.26*0.32*0.29*0.31*0.34*0.33*0.33*0.37*0.38*-----
Interest Expenses0%19.0019.0020.009.006.006.006.0013.0014.0016.0019.0016.0011.0011.0011.0011.0011.0015.0015.0020.0015.00
Income Taxes-119.3%-28.00145-81.00-28.50144-10254.00-25.5010322.0022.0042.0036.001185.0030.0036.0053.009.0012.0044.00
Earnings Before Taxes-778.7%-782-89.00-78.00-167-3,672-63714087.00420207169299215165178269270346233209232
EBT Margin100.0%--0.90*-1.02*-0.95*-0.87*0.00*0.18*0.20*0.26*0.22*0.24*0.26*0.26*0.26*0.30*0.32*-----
Net Income-222.2%-754-2343.00-139-3,816-53586.0011331718514725717947.00173239234296233210199
Net Income Margin100.0%--0.94*-1.01*-0.96*-0.88*0.00*0.15*0.17*0.21*0.19*0.18*0.20*0.20*0.21*0.26*0.28*-----
Free Cashflow-100.0%-58.00-42.0059.00-11854.00111212-324209240344105201241386-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-14.0%10,12211,77411,81112,25211,25615,44815,27415,21715,0638,6758,7557,5857,4047,2487,2617,3167,0896,9737,3906,9596,759
  Current Assets-22.2%2,5063,2233,1723,5612,4872,8912,7552,7132,4515,3105,6424,4834,3294,1944,3244,4514,2224,1564,5454,4904,262
    Cash Equivalents-40.3%9271,5531,4942,0111,0001,2891,3511,2321,0804,1964,4331,8101,7611,7701,9912,0421,8151,9432,2701,1441,346
  Inventory-0.3%615617586568559518465431401380364372415435384359417420412386374
  Net PPE-2.7%1,0401,0691,0821,0911,0681,0551,0341,0241,0099159159229108908908898758548528341,060
  Goodwill-22.0%2,5273,2393,2393,2393,2387,1587,1137,1137,098966897897897894824897824824831831831
  Current Liabilities-35.6%1,4822,3032,2302,7732,6692,8811,4901,0939148741,2681,2441,1151,1151,0546656196121,2411,8041,735
    LT Debt, Current-------499----511507503499---6318381,107
    LT Debt, Non Current------------6736666596521,1411,1311,1201,112890860
Shareholder's Equity-10.0%5,8986,5556,6936,5996,73110,44410,89510,74010,5935,1804,9224,6944,7004,5634,6354,6134,4394,3324,0703,8453,594
  Retained Earnings-82.8%1579111,1451,1421,2815,0975,6325,4855,3725,0554,8704,7234,4664,2874,2404,0673,8283,5943,2983,0832,872
  Additional Paid-In Capital1.0%9,4879,3979,3119,2079,1299,0338,9578,9388,8493,9933,9143,8153,7373,6493,6313,5603,5103,4363,3853,2903,093
Accumulated Depreciation----962---796---678---------
Shares Outstanding-100.0%-158158158157157157157152146146146146147147147147147147147147
Minority Interest-------------------85.0087.0091.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations32.4%139,000,000105,000,00010,000,000147,000,000-52,000,000125,000,000172,000,000282,000,000-272,000,000253,000,000282,000,000406,000,000153,000,000240,000,000281,000,000443,000,000267,000,000143,000,000198,000,000300,000,000292,000,000
  Share Based Compensation-17.9%87,000,000106,000,00093,000,000100,000,00083,000,00091,000,00092,000,00098,000,000509,000,00080,000,00067,000,00078,000,00061,000,00016,000,00039,000,00049,000,00046,000,00048,000,00051,000,00047,000,00048,000,000
Cashflow From Investing-43.2%-53,000,000-37,000,000-56,000,000-102,000,000-250,000,000-165,000,000-74,000,000--2,448,000,0003,000,0001,376,000,000-34,000,000-65,000,000-320,000,000-135,000,000-104,000,000-218,000,00079,000,000988,000,000-348,000,000-940,000,000
Cashflow From Financing-23466.7%-707,000,000-3,000,000-473,000,000956,000,00028,000,000-5,000,00021,000,000-129,000,000-394,000,000-496,000,000968,000,000-331,000,000-101,000,000-143,000,000-191,000,000-115,000,000-173,000,000-549,000,000-60,000,000-154,000,000651,000,000
  Buy Backs------------281,000,000125,000,000142,000,000188,000,00063,000,000198,000,000-63,000,00098,000,000-

ILMN Income Statement

2023-10-01
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Oct. 01, 2023
Oct. 02, 2022
Oct. 01, 2023
Oct. 02, 2022
Revenue:    
Total revenue$ 1,119$ 1,115$ 3,382$ 3,501
Cost of revenue:    
Amortization of acquired intangible assets4746143125
Total cost of revenue4353981,3121,201
Gross profit6847172,0702,300
Operating expense:    
Research and development3153251,013975
Selling, general and administrative3031461,127865
Goodwill and intangible impairment8213,9148213,914
Legal contingency and settlement(1)(11)14598
Total operating expense1,4384,3742,9756,352
Loss from operations(754)(3,657)(905)(4,052)
Other income (expense):    
Interest income133474
Interest expense(19)(6)(59)(17)
Other expense, net(22)(12)(33)(103)
Total other expense, net(28)(15)(45)(116)
Loss before income taxes(782)(3,672)(950)(4,168)
(Benefit) provision for income taxes(28)1443697
Net loss$ (754)$ (3,816)$ (986)$ (4,265)
Loss per share:    
Basic (in dollars per share)$ (4.77)$ (24.26)$ (6.23)$ (27.13)
Diluted (in dollars per share)$ (4.77)$ (24.26)$ (6.23)$ (27.13)
Shares used in computing loss per share:    
Basic (in shares)158157158157
Diluted (in shares)158157158157
Product revenue    
Revenue:    
Total revenue$ 941$ 963$ 2,864$ 3,039
Cost of revenue:    
Cost of revenue293280884866
Service and other revenue    
Revenue:    
Total revenue178152518462
Cost of revenue:    
Cost of revenue$ 95$ 72$ 285$ 210

ILMN Balance Sheet

2023-10-01
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Oct. 01, 2023
Jan. 01, 2023
Current assets:  
Cash and cash equivalents$ 927$ 2,011
Short-term investments626
Accounts receivable, net690671
Inventory, net615568
Prepaid expenses and other current assets268285
Total current assets2,5063,561
Property and equipment, net1,0401,091
Operating lease right-of-use assets581653
Goodwill2,5273,239
Intangible assets, net3,0293,285
Other assets439423
Total assets10,12212,252
Current liabilities:  
Accounts payable240293
Accrued liabilities1,2421,232
Term notes, current portion0500
Convertible senior notes, current portion0748
Total current liabilities1,4822,773
Operating lease liabilities698744
Term notes1,4891,487
Other long-term liabilities555649
Stockholders’ equity:  
Common stock22
Additional paid-in capital9,4879,207
Accumulated other comprehensive income213
Retained earnings1571,142
Treasury stock, at cost(3,769)(3,755)
Total stockholders’ equity5,8986,599
Total liabilities and stockholders’ equity$ 10,122$ 12,252
ILMN
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
 CEO
 WEBSITEwww.illumina.com
 EMPLOYEES11500

Illumina Inc Frequently Asked Questions


What is the ticker symbol for Illumina Inc? What does ILMN stand for in stocks?

ILMN is the stock ticker symbol of Illumina Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Illumina Inc (ILMN)?

As of Thu Dec 07 2023, market cap of Illumina Inc is 18.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ILMN stock?

You can check ILMN's fair value in chart. The fair value of Illumina Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Illumina Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ILMN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Illumina Inc a good stock to buy?

The fair value guage provides a quick view whether ILMN is over valued or under valued. Whether Illumina Inc is cheap or expensive depends on the assumptions which impact Illumina Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ILMN.

What is Illumina Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, ILMN's PE ratio (Price to Earnings) is -16.46 and Price to Sales (PS) ratio is 4.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ILMN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Illumina Inc's stock?

In the past 10 years, Illumina Inc has provided 0.015 (multiply by 100 for percentage) rate of return.